Ardelyx Announces NKF Poster on Tenapanor in Dialysis CKD

Key Takeaways

• Ardelyx said an accepted NKF poster will examine long-term serum phosphate, electrolyte, and nutrition biomarker findings in adults with CKD on dialysis.
• The poster description indicates tenapanor lowered serum phosphate without changes in other serum electrolytes in dialysis patients with hyperphosphatemia.
• XPHOZAH is described for adults on dialysis who had an inadequate response to phosphate binders or were intolerant of any dose of phosphate binder therapy, and diarrhea was the main safety point highlighted.

Ardelyx said an abstract was accepted for NKF Spring Clinical Meetings poster presentation. The poster will address long-term effects of XPHOZAH (tenapanor) on serum electrolytes and selected nutrition biomarkers in adults with chronic kidney disease on dialysis. The display is scheduled for May 7, 2026.

Ardelyx listed the poster as G-353 and scheduled its display in New Orleans for May 7, 2026, from 5:15 to 7:30 PM CT. The description points to lower serum phosphate without shifts in other serum electrolytes among dialysis patients with hyperphosphatemia. It also says the poster will address long-term effects on selected nutrition biomarkers. Pablo E. Pergola, Yang Yang, Suling Zhao, Elizabeth Stremke, Susan Edelstein, and David M. Spiegel were listed as authors. The presentation is part of the NKF Spring Clinical Meetings schedule for May 7 through May 10, 2026.

Ardelyx described XPHOZAH as approved to reduce serum phosphorus in adults with CKD on dialysis. The company said it is used as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. Ardelyx also described the drug as acting locally in the gut by inhibiting NHE3, which reduces phosphate absorption through the paracellular pathway. In the same notice, the company characterized XPHOZAH as the first and only phosphate absorption inhibitor and as a single tablet taken twice daily.

In clinical trials, diarrhea was the most common adverse effect highlighted for XPHOZAH. Ardelyx reported diarrhea in 43% to 53% of treated patients across the cited studies, with severe diarrhea reported in 5%. The company said treatment should be discontinued if severe diarrhea develops. Ardelyx also listed contraindications in children younger than 6 years and in patients with known or suspected mechanical gastrointestinal obstruction.

Ardelyx also said it will sponsor a peer exchange at the same meeting on May 8, 2026, at 12:15 PM CT. The session is framed around treating hyperphosphatemia and managing side effects in dialysis care. Ardelyx said the program will review efficacy and safety data for XPHOZAH. It will also cover practical considerations for add-on use in dialysis patients on phosphate binders whose serum phosphorus remains above guideline-established targets.